Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-08-30
2011-08-30
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S465000, C424S474000, C514S397000, C514S461000, C514S974000, C514S960000
Reexamination Certificate
active
08007825
ABSTRACT:
Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto, or alternatively may be within particles and/or the matrix of such dosage forms, in coatings applied to such particles, or on the surface of such coated particles. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient. Other oral dosage forms include thin film strips, gummi, foam tabs, and lozenges.
REFERENCES:
patent: 4173626 (1979-11-01), Dempski et al.
patent: 4479969 (1984-10-01), Bakai et al.
patent: 4820506 (1989-04-01), Kleinberg et al.
patent: 4820524 (1989-04-01), Berta
patent: 4851226 (1989-07-01), Julian et al.
patent: 4863742 (1989-09-01), Panoz et al.
patent: 4906478 (1990-03-01), Valentine et al.
patent: 4927816 (1990-05-01), Ester
patent: 4980170 (1990-12-01), Schneider et al.
patent: 4984240 (1991-01-01), Keren-Zvi et al.
patent: 5075114 (1991-12-01), Roche
patent: 5156845 (1992-10-01), Grodberg
patent: 5228916 (1993-07-01), Berta
patent: 5260072 (1993-11-01), Roche et al.
patent: 5275822 (1994-01-01), Valentine et al.
patent: 5286497 (1994-02-01), Hendrickson et al.
patent: 5387614 (1995-02-01), Schoenwald et al.
patent: 5489436 (1996-02-01), Hoy et al.
patent: 5571528 (1996-11-01), Lee et al.
patent: 5580880 (1996-12-01), Handa et al.
patent: 5912013 (1999-06-01), Rudnic et al.
patent: 5948430 (1999-09-01), Zerbe et al.
patent: 5962503 (1999-10-01), Ekstrom et al.
patent: 6090401 (2000-07-01), Gowan, Jr. et al.
patent: 6103260 (2000-08-01), Luber et al.
patent: 6177096 (2001-01-01), Zerbe et al.
patent: 6258381 (2001-07-01), Luber et al.
patent: 6270790 (2001-08-01), Robinson et al.
patent: 6270805 (2001-08-01), Chen et al.
patent: 6277409 (2001-08-01), Luber et al.
patent: 6322819 (2001-11-01), Burnside et al.
patent: 6419903 (2002-07-01), Xu et al.
patent: 6432442 (2002-08-01), Buehler et al.
patent: 6596298 (2003-07-01), Leung et al.
patent: 6709678 (2004-03-01), Gruber
patent: 6837696 (2005-01-01), Sowden et al.
patent: 2002/0068088 (2002-06-01), Gruber
patent: 2002/0122778 (2002-09-01), Wolfson
patent: 2003/0070584 (2003-04-01), Gulian et al.
patent: 2003/0072729 (2003-04-01), Szymczak et al.
patent: 2003/0072731 (2003-04-01), Guilian et al.
patent: 2004/0247675 (2004-12-01), Gruber
patent: 2006/0029665 (2006-02-01), Singh
patent: 1219291 (2002-03-01), None
patent: 2 864 01 (2005-07-01), None
patent: WO 88/06893 (1988-09-01), None
patent: WO 00/25744 (2000-05-01), None
patent: WO 01/54499 (2001-08-01), None
patent: WO 02/49607 (2002-06-01), None
patent: WO 02/80886 (2002-10-01), None
patent: WO 2004/096174 (2004-11-01), None
patent: WO 2005/063203 (2005-07-01), None
Yashiro et al., “Changes in microsomal lysophospholipid acyltransferase activity are correlated with rat parotid gland enlargement induced by chronic administration of isoproterenol,” J. Biochem., 115, 1040-1046 (1994).
Webber, M et. al., “Atropine as a possible agent to prevent Xerostomia in patients treated with iodine-131 for carcinoma of thyroid,” Journal of Nuclear Medicine, vol. 12, No. 6, Jun. 1971, pp. 482-483.
Bagheri et al., “Pharmacokinetic Study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants,” British Jl. Clinical Pharmacology, 1994; 37, pp. 93-96.
Bruck et al., “Xerostomie and asialia caused by psychotropic drugs and treatment with TPMP,” NR.33-35 Wien Med Wochenschr 495-500 (Aug. 17, 1974). (“Bruck”).
Levin, S. L., “Salivation from the denervated Human Parotid gland induced by Pirenzepine and Telenzepine,” Eur. Jl. Clinical Pharmacology, (1991)41, pp. 613-614.
Kawashiro et. al., “Pharmacokinetics of SNI-2011 (2): Absorption, Restriction, Excretion and Metabolism of 14C-SNI-2011 in Dogs,” Xenobio. Metabol. and Dispos., 16(6): 553-557 (2001).
USP 24, 2000 Version, pp. 19-20 and p. 856 (1999).
Lachman, et al., The Theory and Practice of Industrial Pharmacy, Chapter 11 (3rdEd. 1986).
Lieberman, et. Al., “Pharmaceutical Dosage Forms—Tablets,” vol. 2, pp. 213-217 and 327-329 (2nded 1990).
Bruck (English Translation).
Fox, “Salivary Enhancement Therapies”,Caries Research, vol. 38, No. 3 (May 2004) pp. 241-246.
Iwabuchi et al, “Sialogogic Activities of SNI-2011 Compared with those of Pilocarpine and McN-A-343 in Rat Salivary Glands: Identification of a Potential Therapeutic Agent for Treatment of Sjorgen's Syndrome”,General Pharmacology, vol. 25, No. 1 (Jan. 1994) pp. 123-129.
Robinson Ronni
Wynn David W.
Anderson James
Mc-Neil-PPC, Inc.
Polansky Gregg
LandOfFree
Oral compositions containing a salivation inducing agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral compositions containing a salivation inducing agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral compositions containing a salivation inducing agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2771405